Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailAnticorps monoclonaux en cardiologie.
Legrand, Victor ULg

in Revue medicale de Liege (2009), 64(5-6), 310-2

Clinical efficacy of antiplatelet agents administration to reduce ischemic complications has supported the concept of atherothrombosis and plaque rupture. Specifically, administration of monoclonal ... [more ▼]

Clinical efficacy of antiplatelet agents administration to reduce ischemic complications has supported the concept of atherothrombosis and plaque rupture. Specifically, administration of monoclonal antibody against platelet membrane receptor glycoprotein IIb/IIa was shown to be highly effective whenever percutaneous intervention is performed in the setting of unstable coronary syndrome. The in-hospital use of glycoprotein IIb/IIIa is unanimously recommended in these situations. [less ▲]

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailAnticorps monoclonaux en diabétologie : jusqu’au bout du rêve ?
Philips, Jean-Christophe ULg; Keymeulen, B.; Mathieu, C. et al

in Revue Médicale de Liège (2009), 64(5-6), 3327-333

SUMMARY : Type 1 diabetes is characterized by the autoimmune- mediated destruction of the insulin-producing beta cells of the pancreatic islets of Langerhans. Several cells are potentially implicated in ... [more ▼]

SUMMARY : Type 1 diabetes is characterized by the autoimmune- mediated destruction of the insulin-producing beta cells of the pancreatic islets of Langerhans. Several cells are potentially implicated in the selective destruction of beta cells, including the beta cells themselves, and T-lymphocytes and B- lymphocytes that are working as antigen-presenting cells. Both types of lymphocytes play also a role in the progressive loss of graft function after islet transplantation. Therefore, immunotherapy may represent a great opportunity to prevent, treat or even cure type 1 diabetes, and the input of monoclonal antibodies (mAb) appears crucial in such a strategy. The concept has first been validated in various animal models, especially the classical one of the NOD mouse. During recent years, promising results of a few clinical trials have been published with the administration of anti-CD3 mAbs targeting T lymphocytes at the time of diagnosis of type 1 diabetes. Results showed a more sustained residual insulin secretion during the following months associated with a reduction in insulin needs. Interesting results may also be expected from the use of anti-CD20 mAbs targeting B lymphocytes. Finally, when considering immunosuppressive therapies after beta-cell transplantation, mAbs, especially those blocking interleukin-2, are already used in clinical practice, but new trials are expected with mAbs targeting T or B lymphocytes. Thus, mAbs might be efficacious in a near future in the prevention (when administered early in the natural course of the disease, in high risk patients) and the treatment of type 1 diabetes, and therefore could avoid, or at least minimize, the constraints of intensive subcutaneous insulin therapy. [less ▲]

Detailed reference viewed: 178 (4 ULg)
Full Text
Peer Reviewed
See detailLes anticorps monoclonaux en hématologie en 2009
Bonnet, Christophe ULg; Beguin, Yves ULg; De Prijck, Bernard ULg et al

in Revue Médicale de Liège (2009), 64

Directed against the CD20 antigen on B lymphocytes, rituximab (MabThera) is now incorporated in the first line therapy of symptomatic follicular as well as diffuse large B cell non-Hodgkin's lymphoma and ... [more ▼]

Directed against the CD20 antigen on B lymphocytes, rituximab (MabThera) is now incorporated in the first line therapy of symptomatic follicular as well as diffuse large B cell non-Hodgkin's lymphoma and offers superior response and survival rates. 90Y ibritumomab tiuxetan (Zevalin) combines the specificity of rituximab for the CD20 antigen and the therapeutic effect of β irradiation. Given in monotherapy, it constitutes an interesting alternative therapy for follicular lymphomas in second relapse. Alemtuzumab (MabCampath) recognizes the CD52 antigen and offers encouraging results in chronic lymphocytic leukemia resistant to classical chemotherapy. [less ▲]

Detailed reference viewed: 236 (14 ULg)
Full Text
Peer Reviewed
See detailLes anticorps monoclonaux en neurologie.
JEDIDI, Zayd ULg; Jedidi, Haroun ULg; Moonen, Gustave ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 305-9

Since their inception in the 1970's, monoclonal antibody therapies became increasingly efficient and common in numerous medical conditions and their use in neurology has been boosted during the last ... [more ▼]

Since their inception in the 1970's, monoclonal antibody therapies became increasingly efficient and common in numerous medical conditions and their use in neurology has been boosted during the last couple of years with the rise of natalizumab (Tysabri). Furthermore, if most monoclonal antibodies currently assessed in neurologic conditions remain considered as experimental, they may soon become first-line approved treatments in a broad range of neuromuscular and demyelinating diseases. Since the introduction of new therapies is likely to unravel specific adverse events and sui generis iatrogenic disorders, it is important to be able to recognize the side-effects of monoclonal antibodies delivered for neurological or non-neurological diseases. [less ▲]

Detailed reference viewed: 193 (22 ULg)
Full Text
Peer Reviewed
See detailLes anticorps monoclonaux en thérapeutique.
Scheen, André ULg; Moutschen, Michel ULg

in Revue Médicale de Liège (2009), 64(5-6), 233-6

Detailed reference viewed: 95 (7 ULg)
Full Text
Peer Reviewed
See detailLes anticorps monoclonaux en transplantation rénale
Bonvoisin, Catherine ULg; Weekers, Laurent ULg; Grosch, Stéphanie ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 287-292

Renal transplantation is the best treatment for end-stage renal disease, but requires efficient immunosuppressive therapy. The latter has evolved over recent years with the development of more powerful ... [more ▼]

Renal transplantation is the best treatment for end-stage renal disease, but requires efficient immunosuppressive therapy. The latter has evolved over recent years with the development of more powerful drugs and of monoclonal antibodies with very specific target. The first monoclonal antibodies, acting against the interleukin 2 receptor, named basiliximab and daclizumab, have showed an excellent tolerance profile and efficacy to reduce acute graft rejection. However, in spite of these properties, the development of delayed graft function or the graft and patient survivals at 1 year were not modified by the use of such specific treatment. One potential advantage could yet be a decreasing need for corticosteroids and sometimes calcineurin inhibitors which could provide some long term benefits for the renal graft, but also the patient. Alemtuzumab, another monoclonal antibody, aimed at the membrane glycoprotein CD52, can also decrease the incidence of acute rejection and the depth of the required immunosuppressive therapy. Other antibodies are still in development with some interesting preliminary results which however demand confirmation in larger studies. [less ▲]

Detailed reference viewed: 65 (1 ULg)
Full Text
Peer Reviewed
See detailANTICORPS MONOCLONAUX ET CANCER DU SEIN: Actualités thérapeutiques
Collignon, Joëlle ULg; Gennigens, Christine ULg; Rorive, Andrée ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 279-83

About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of ... [more ▼]

About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of targeted therapies in subgroups of cancers. One of the first validation of targeted therapy is the anti-HER-2 monoclonal antibody trastuzumab (Herceptin) in patients with overexpression of human epidermal growth factor receptor type 2 (HER2) occurring in 20 to 25% of invasive breast carcinoma. Trastuzumab binds the extracellular juxtamembrane domain and is only active in tumor with HER2 gene amplification detected by fluorescence in situ hybridization (FISH). The results from randomized trials have rapidly lead to the approvement of the drug in the metastatic and then in the adjuvant setting. Another targeted therapy, also approved in the treatment of breast cancer, is the monoclonal antibody bevacizumab with an anti-VEGF (Vascular Endothelial Growth Factor) activity. We will review the benefit of these targeted therapies in breast cancer and their role in the treatment of breast cancer. [less ▲]

Detailed reference viewed: 486 (43 ULg)
Full Text
Peer Reviewed
See detailLes anticorps monoclonaux
Thiry, Etienne ULg; Pastoret, Paul-Pierre ULg

in Annales de Médecine Vétérinaire (1981), 125

Detailed reference viewed: 11 (1 ULg)
Peer Reviewed
See detailAnticyclonic eddies in the deep eastern Black Sea in summer-autumn 1999 (satellite and ship-borne observations
Ginzburg, Anna I.; Zatsepin, Andrey; Kostianoy, Andrey G. et al

in Earth Observation and Remote Sensing (2001), 5

Detailed reference viewed: 27 (7 ULg)
Full Text
Peer Reviewed
See detailAntidepressant medications and osteoporosis
Rizzoli, R; Cooper, C; Reginster, Jean-Yves ULg et al

in BONE (2012), 51

Detailed reference viewed: 16 (1 ULg)
See detailAntidepressant use and fracture risk: a meta-analysis
Bruyère, Olivier ULg

Conference (2012, March 24)

Detailed reference viewed: 20 (1 ULg)
Full Text
Peer Reviewed
See detailLes antidépresseurs dans la dépression majeure: La dose a-t-elle de l'importance?
PITCHOT, William ULg

in Acta Psychiatrica Belgica (2013)

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailLes antidépresseurs du futur : rôle du système glutamatergique.
PITCHOT, William ULg; Scantamburlo, Gabrielle ULg; Ansseau, Marc ULg

in Revue Médicale de Liège (2011), 66(4), 195-198

Detailed reference viewed: 27 (0 ULg)
See detailAntidépresseurs et risque fracturaire
Bruyère, Olivier ULg

Scientific conference (2012, February 24)

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailAntidépresseurs et syndrome d'interruption
PITCHOT, William ULg

in Acta Psychiatrica Belgica (2013)

Detailed reference viewed: 17 (1 ULg)
Full Text
See detailLes antidépresseurs
Ansseau, Marc ULg; PITCHOT, William ULg

in Rouillon, Fréderic (Ed.) Manuel de Psychiatrie (2012)

Detailed reference viewed: 22 (5 ULg)
Full Text
See detailLes antidépresseurs.
Ansseau, Marc ULg; Pitchot, William ULg

in Guelfi, J. D.; Rouillon, F. (Eds.) Manuel de Psychiatrie (2007)

Detailed reference viewed: 25 (3 ULg)